One issue affecting the NTI market is that shareholders mainly fit into one of two categories. There are those who are in the stock for Mente/Autism. And there are those who are in the stock for its wider medicinal cannabis potential.
Many in the first category may not welcome Brian Leedman's cannabis inititatives and are sellers.
It may take time for them to exit...and for the $100m MC forcast to be realized.
As for me, I'm in the second category. I notate NTI receipts in the September quarter totalled $12k. This suggests Mente is a dud.
I think @bleedman should pursue the option of selling the Mente tech so that he can focus on the vast potential in healing Alzheimer's Disease and Huntington's Disease.
NTI Price at posting:
3.3¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)